Insmed (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 76,520 Shares

Key Points

• Insmed insider Orlov Nicole Schaeffer sold 76,520 shares of the company's stock for a total of $11,129,834, significantly reducing their stake by 67.73%.
• The company's stock recently traded down to $143.14, with a market cap of $30.26 billion and a fifty-two week high of $149.08.
• Insmed reported a quarterly EPS of ($1.70), missing analysts' expectations and resulting in a negative net margin of 259.82%, despite an 18.9% increase in revenue year-over-year.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company's stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the sale, the insider directly owned 36,461 shares of the company's stock, valued at $5,303,252.45. The trade was a 67.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Insmed Stock Down 0.8%

INSM traded down $1.10 on Friday, reaching $144.76. The company's stock had a trading volume of 5,624,066 shares, compared to its average volume of 1,971,056. The stock has a market cap of $30.60 billion, a price-to-earnings ratio of -25.35 and a beta of 0.97. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $149.08. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business's 50 day moving average is $124.17 and its 200 day moving average is $94.19.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same period in the prior year, the company posted ($1.94) EPS. The company's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Trading of Insmed

Several large investors have recently added to or reduced their stakes in INSM. M&T Bank Corp increased its holdings in shares of Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after purchasing an additional 147 shares during the period. Snowden Capital Advisors LLC lifted its holdings in shares of Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after buying an additional 158 shares during the last quarter. First Horizon Advisors Inc. lifted its position in Insmed by 24.8% in the second quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 186 shares during the period. ORG Partners LLC raised its stake in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares in the last quarter.

Analyst Upgrades and Downgrades

INSM has been the topic of several research reports. Truist Financial upped their price objective on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Morgan Stanley increased their price target on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. UBS Group increased their price target on Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Leerink Partners increased their price target on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Finally, Citigroup upgraded Insmed to a "buy" rating in a research report on Tuesday, June 10th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $139.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.